Science & Technology
Science and Technology
Science and Technology
Tue, April 12, 2011
LANCASTER, Calif.--([ BUSINESS WIRE ])--Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, announced today the release of [ MedChem Studio ]a" version 2.0 with an impressive set of expanded and powerful capabilities for data mining and de novo molecule design.
MedChem Studio 2.0 now includes:
- Our new [ MedChem Designer ]a" advanced molecule drawing tool
- Greatly expanded multidimensional graphics output
- Enhanced import capabilities for molecular structure files
- Enhanced capabilities for exporting results
- Additional improvements to our industry-best structure depictions
Dr. David Miller, team leader for discovery cheminformatics at Simulations Plus, said, aMedChem Studio has been evolving for more than five and a half years, beginning as ClassPharmera" for data mining, but steadily growing in sophistication and power for both data mining and new molecule design. Wea™ve accomplished this while maintaining both a friendly graphical user interface for focused studies as well as sophisticated algorithms for automatic processing of large structure libraries. The programa™s tight integration with our best-in-class [ ADMET Predictor ]a" software provides what we believe is the most powerful in silico molecule design capability available today.a
Walt Woltosz, chairman and chief executive officer of Simulations Plus, added: aWea™re excited about the power of this new MedChem Studio/MedChem Designer product, especially when combined with ADMET Predictor. Medicinal chemists throughout the industry are learning more and more to think in terms of multidimensional optimization of molecular structures, rather than focusing only on the strength with which the molecule binds to the target protein. With the MedChem Studio/MedChem Designer/ADMET Predictor combination, chemists now have an unprecedented capability to see how changes in molecular structures affect not just one or a handful of properties, but over 120 properties from the industrya™s top-ranked property prediction program, ADMET Predictor. We believe that this represents the future for drug discovery a" no other technology offers as much potential for reducing the time and money required to discover new structures that can become tomorrowa™s medicines.a
About Simulations Plus, Inc.
Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation and modeling software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. The Companya™s [ Words+ ], Inc., wholly owned subsidiary provides augmentative communication systems and other technologies for persons with disabilities. Simulations Plus is headquartered in Southern California. For more information, visit our web site at [ www.simulations-plus.com ].
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995a" With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like abelieve,a aexpecta and aanticipatea mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: the acceptance by our customers of MedChem Studio/MedChem Designer and their capabilities, our ability to maintain our competitive advantages, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with the U.S. Securities and Exchange Commission.
